Neonatal Seizure Registry Developmental Functional EValuation (NSR-DEV)

新生儿癫痫登记发育功能评估 (NSR-DEV)

基本信息

项目摘要

PROJECT SUMMARY Neonatal seizures due to brain injury (acute symptomatic seizures) are associated with high risk of neurodevelopmental disability in infancy. Although prognosis in early childhood is a critical question for parents and providers, outcomes beyond infancy are largely unknown. Further, parents of infants with neonatal seizures are at risk for mental health disorders, which can undermine their ability to care for a child with medical complexity and may contribute to impaired child development. The proposed “Neonatal Seizure Registry – Developmental functional EValuation (NSR-DEV)” study will test the central hypothesis that risk factors for developmental disabilities can be identified in infancy and are modified by parent well-being. This observational study will leverage the infrastructure of the 9 center Neonatal Seizure Registry, to which we have recruited >300 children with acute symptomatic neonatal seizures (NCT02789176). With support for the current proposal, this unique cohort will be available at ages 2-7 years to participate in annual validated parent- reported developmental evaluations to characterize cognition, adaptive behavior, executive function, behavior, epilepsy and cerebral palsy, as well as in-person, gold standard IQ testing with the WPPSI-IV at age 5 years. Using neonatal clinical, EEG and MRI measures, as well as 3-month EEG, and longitudinal measures of parent well-being, we will build robust models to predict developmental outcome in this high risk population. We will test our hypotheses by pursuing the following specific aims: Aim 1a: Identify predictors of disability in children with prior acute symptomatic neonatal seizures; Aim 1b: Examine risk factors for decline in adaptive behavior in children with prior acute symptomatic neonatal seizures; Aim 2a: Determine whether parent well- being (validated measures for symptoms of anxiety or depression, post-traumatic stress, and resilience) alters the risk for disability among children with prior acute symptomatic neonatal seizures; Aim 2b: Determine whether parent well-being alters the adaptive behavior trajectory in children with prior acute symptomatic neonatal seizures; Aim 3: Build robust risk prediction models for childhood disability after neonatal seizures. This innovative proposal will maintain an existing, multicenter cohort enrolled from US centers that employ state-of-the-art technology for diagnosis and investigation of neonatal seizures, and targets research priorities of parents and clinicians. This carefully designed study will provide novel, clinically-relevant answers to key questions about long term outcomes in this highly vulnerable patient population. Results will inform the subsequent design of neuromodulatory intervention studies and programs designed to optimize parent-related factors with the goal of improving neurodevelopmental outcomes.
项目摘要 由于脑损伤引起的新生儿癫痫发作(急性症状性癫痫发作)与以下高风险相关: 神经发育障碍虽然儿童早期的预后对父母来说是一个关键问题, 和提供者,婴儿期以后的结果在很大程度上是未知的。此外,新生儿的父母 癫痫发作有精神健康障碍的风险,这可能会破坏他们照顾患有癫痫的孩子的能力。 医学上的复杂性,并可能导致儿童发育受损。拟议的“新生儿癫痫” 登记研究-发育功能评估(NSR-DEV)”研究将检验中心假设,即风险 发育障碍的因素可以在婴儿期确定,并通过父母的福祉进行调整。 这项观察性研究将利用9个中心的新生儿癫痫登记处的基础设施, 招募了>300名患有急性症状性新生儿癫痫发作的儿童(NCT 02789176)。通过支持 目前的提议,这个独特的队列将在2-7岁时参加年度验证的父母- 报告的发展评估,以表征认知,适应行为,执行功能,行为, 癫痫和脑瘫,以及在人,金标准智商测试与WPPSI-IV在5岁。 使用新生儿临床、EEG和MRI测量,以及3个月EEG和父母纵向测量 我们将建立强大的模型来预测这一高风险人群的发展结果。 我们将通过追求以下具体目标来测试我们的假设:目标1a:确定残疾的预测因素, 既往有急性症状性新生儿癫痫发作的儿童;目的1b:检查适应性下降的危险因素 有早期急性症状性新生儿癫痫发作的儿童的行为;目的2a:确定父母是否健康- 存在(焦虑或抑郁症状、创伤后压力和恢复力的有效测量)改变 有早期急性症状性新生儿癫痫发作的儿童残疾风险;目标2b:确定 父母的幸福感是否会改变有急性症状儿童的适应行为轨迹 新生儿癫痫发作;目标3:建立新生儿癫痫发作后儿童残疾的可靠风险预测模型。 这项创新提案将维持现有的多中心队列,这些队列从美国中心招募, 用于诊断和调查新生儿癫痫发作的最先进技术,并针对研究重点 家长和临床医生。这项精心设计的研究将提供新颖的,临床相关的答案, 关于这一高度脆弱患者人群的长期结局的问题。结果将通知 随后设计神经调节干预研究和计划,旨在优化父母相关的 以改善神经发育结果为目标的因素。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Toward Equity in Research Participation: Association of Financial Impact With In-Person Study Participation.
实现研究参与的公平:财务影响与亲自研究参与的关联。
  • DOI:
    10.1016/j.pediatrneurol.2023.04.019
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    3.8
  • 作者:
    Shellhaas,RenéeA;Lemmon,MonicaE;Gosselin,BrianN;Sturza,Julie;Franck,LindaS;Glass,HannahC;NeonatalSeizureRegistry
  • 通讯作者:
    NeonatalSeizureRegistry
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hannah Cranley Glass其他文献

Hannah Cranley Glass的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hannah Cranley Glass', 18)}}的其他基金

NSR-GENE (Neonatal Seizure Registry, GEnetics of post-Neonatal Epilepsy)
NSR-GENE(新生儿癫痫登记,新生儿后癫痫遗传学)
  • 批准号:
    10464355
  • 财政年份:
    2022
  • 资助金额:
    $ 103.58万
  • 项目类别:
NSR-GENE (Neonatal Seizure Registry, GEnetics of post-Neonatal Epilepsy)
NSR-GENE(新生儿癫痫登记,新生儿后癫痫遗传学)
  • 批准号:
    10580043
  • 财政年份:
    2022
  • 资助金额:
    $ 103.58万
  • 项目类别:
Neonatal Seizure Registry Developmental Functional EValuation (NSR-DEV)
新生儿癫痫登记发育功能评估 (NSR-DEV)
  • 批准号:
    10330599
  • 财政年份:
    2020
  • 资助金额:
    $ 103.58万
  • 项目类别:
Neonatal Seizure Registry Developmental Functional EValuation (NSR-DEV)
新生儿癫痫登记发育功能评估 (NSR-DEV)
  • 批准号:
    9887172
  • 财政年份:
    2020
  • 资助金额:
    $ 103.58万
  • 项目类别:
HEAL - EEG - Neurophysiologic measures of Epo treatment for hypoxic-ischemic encephalopathy (HIE)
HEAL - 脑电图 - Epo 治疗缺氧缺血性脑病 (HIE) 的神经生理学措施
  • 批准号:
    10200910
  • 财政年份:
    2018
  • 资助金额:
    $ 103.58万
  • 项目类别:
HEAL - EEG - Neurophysiologic measures of Epo treatment for hypoxic-ischemic encephalopathy (HIE)
HEAL - 脑电图 - Epo 治疗缺氧缺血性脑病 (HIE) 的神经生理学措施
  • 批准号:
    9790993
  • 财政年份:
    2018
  • 资助金额:
    $ 103.58万
  • 项目类别:
NRSA Training Core
NRSA 培训核心
  • 批准号:
    10448374
  • 财政年份:
    2016
  • 资助金额:
    $ 103.58万
  • 项目类别:
NRSA Training Core
NRSA 培训核心
  • 批准号:
    10666708
  • 财政年份:
    2016
  • 资助金额:
    $ 103.58万
  • 项目类别:
MRI Mechanisms of Adverse Outcome in Preterm Infants with Seizures
早产儿癫痫发作不良后果的 MRI 机制
  • 批准号:
    8037069
  • 财政年份:
    2010
  • 资助金额:
    $ 103.58万
  • 项目类别:
MRI Mechanisms of Adverse Outcome in Preterm Infants with Seizures
早产儿癫痫发作不良后果的 MRI 机制
  • 批准号:
    8290057
  • 财政年份:
    2010
  • 资助金额:
    $ 103.58万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 103.58万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 103.58万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 103.58万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 103.58万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 103.58万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 103.58万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 103.58万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 103.58万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 103.58万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 103.58万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了